Outcomes following repeat exenteration for locally advanced pelvic malignancy. (15th November 2020)

• Record Type: Journal Article
• Authors: Blake, Joshua; Koh, Cherry E.; Steffens, Daniel; De Robles, Marie Shella; Brown, Kilian; Lee, Peter; Austin, Kirk; Solomon, Michael J.
• Is Part Of: Colorectal disease. Volume 23:Number 3(2021)
• Page Start: 646
• Page End: 652
• Publication Date: 2020-11-15
• Subjects: cancer -- pelvic disease -- pelvic exenteration -- rectal malignancy -- repeat exenteration -- surgery; Colon (Anatomy) -- Diseases -- Periodicals; Rectum -- Diseases -- Periodicals; 616.34
• DOI: 10.1111/codi.15402
• Languages: English
• ISSNs: 1462-8910

Abstract

Abstract: Aim: This study aims to assess surgical outcomes and survival following first, second and third pelvic exenterations for pelvic malignancy. Method: Consecutive patients undergoing pelvic exenteration for pelvic malignancy at a quaternary referral centre from January 1994 and December 2017 were included. Demographics and surgical outcomes were compared between patients who underwent first, second and third pelvic exenterations by generalized mixed modelling with repeated measures. Survival was assessed using Cox proportional hazards models and Kaplan–Meier plots. Results: Of the 642 exenterations reviewed, 29 (4.5%) were second and 6 (0.9%) were third exenterations. Patients selected for repeat exenteration were more likely to have asymptomatic local recurrences detected on routine surveillance ( P < 0.001). Postoperative wound complications increased with repeat exenteration (6%, 17%, 33%; P = 0.003, respectively). Additionally, postoperative length of stay increased from 27 to 38 and 48 days, respectively ( P = 0.004). Median survival from first exenteration was 4.75, 5.30 and 8.14 years respectively amongst first, second and third exenteration cohorts ( P = 0.849). Median survival from the most recent exenteration was 4.75 years after a first exenteration, 2.02 years after a second exenteration and 1.45 years after a third exenteration ( P = 0.0546). Conclusion: This study demonstrates that repeat exenteration for recurrent pelvic malignancy is feasible but is associated with increased complication rates and length of admission and reduced likelihood of attaining R0 margin. Moreover, these data indicate that repeat exenteration does not afford a survival advantage compared with patients having a single exenteration. These data suggest that repeat exenteration for recurrent pelvic malignancy may be of questionable therapeutic value.